The herpes simplex virus type 1 DNA polymerase processivity factor, UL42, does not alter the catalytic activity of the UL9 origin-binding protein but facilitates its loading onto D...

by Trego, Kelly S., Zhu, Yali, Parris, Deborah S.
Published 2005

Changes in subcellular localization reveal interactions between human cytomegalovirus terminase subunits

by Wang, Jian Ben, Zhu, Yali, McVoy, Michael A, Parris, Deborah S
Published 2012

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

by Nemunaitis, John J, Small, Karen A, Kirschmeier, Paul, Zhang, Da, Zhu, Yali, Jou, Ying-Ming, Statkevich, Paul, Yao, Siu-Long, Bannerji, Rajat
Published 2013

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

by Gojo, Ivana, Sadowska, Mariola, Walker, Alison, Feldman, Eric J., Iyer, Swaminathan Padmanabhan, Baer, Maria R., Sausville, Edward A., Lapidus, Rena G., Zhang, Da, Zhu, Yali, Jou, Ying-Ming, Poon, Jennifer, Small, Karen, Bannerji, Rajat
Published 2013

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia

by Flynn, Joseph, Jones, Jeffrey, Johnson, Amy J., Andritsos, Leslie, Maddocks, Kami, Jaglowski, Samantha, Hessler, Joshua, Grever, Michael R., Ellie, Im, Zhou, Honghong, Zhu, Yali, Zhang, Da, Small, Karen, Bannerji, Rajat, Byrd, John C.
Published 2015